Login

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q3 FY2020
As of Oct 31, 2020
Q2 FY2020
As of Jun 30, 2020
Q1 FY2020
As of Mar 31, 2020
Q4 FY2019
As of Dec 31, 2019
Q4 FY2018
As of Dec 31, 2018
Q4 FY2017
As of Dec 31, 2017
Q4 FY2016
As of Dec 31, 2016
Q4 FY2015
As of Dec 31, 2015
Q4 FY2014
As of Dec 31, 2014
Q4 FY2013
As of Dec 31, 2013
Q4 FY2012
As of Dec 31, 2012
Q4 FY2011
As of Dec 31, 2011
Assets:
Cash and cash equivalents
Predecessor
Total cash and cash equivalents
Restricted cash
Predecessor
Total restricted cash
Other receivable
Accounts receivable, net
Predecessor
Total accounts receivable, net
Materials and supplies
Predecessor
Total materials and supplies
Deferred costs, current
Predecessor
Total deferred costs, current
Prepaid expenses and other current assets
Predecessor
Total prepaid expenses and other current assets
Current assets
Predecessor
Total current assets
Property and equipment, net
Predecessor
Total property and equipment, net
Long-term receivable
Predecessor
Total long-term receivable
Receivable from unconsolidated subsidiaries
Intangible asset
Investment in unconsolidated subsidiaries
Other assets
Predecessor
Total other assets
Predecessor
Total assets
Liabilities and shareholders' equity:
Accounts payable
Predecessor
Total accounts payable
Accrued expenses
Predecessor
Total accrued expenses
Accrued interest
Predecessor
Total accrued interest
Deferred revenue, current
Predecessor
Total deferred revenue, current
Current liabilities
Predecessor
Total current liabilities
Long-term debt
Payable to unconsolidated subsidiaries
Deferred revenue
Other long-term liabilities
Predecessor
Total other long-term liabilities
Liabilities not subject to compromise
Predecessor
Total liabilities not subject to compromise
Liabilities subject to compromise
Predecessor
Total liabilities subject to compromise
Total long-term liabilities
Total liabilities
Shareholders' equity:
Common shares, $0.01 par value per share, 82,500 shares authorized and issued and 75,203 and 75,007 shares outstanding as of September 30, 2020 and December 31, 2019, respectively
Predecessor
Total common shares, $0.01 par value per share, 82,500 shares authorized and issued and 75,203 and 75,007 shares outstanding as of September 30, 2020 and December 31, 2019, respectively
Additional paid-in capital
Predecessor
Total additional paid-in capital
Accumulated other comprehensive loss
Predecessor
Total accumulated other comprehensive loss
Treasury shares, at cost
Accumulated deficit
Predecessor
Total accumulated deficit
Predecessor
Total shareholders' equity
Predecessor
Total liabilities and shareholders' equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support